Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Chugai Pharmaceutical Acquires Renalys Pharma in $200M Deal for IgAN Asset Sparsentan

Chugai Pharmaceutical Acquires Renalys Pharma in $200M Deal for IgAN Asset Sparsentan

Chugai Pharmaceutical, a subsidiary of Roche, has announced a significant move in the rare kidney disease space with the acquisition of Tokyo-based Renalys Pharma for up to 31 billion yen ($202 million). The deal centers around the rights to sparsentan, a promising treatment for IgA nephropathy (IgAN), in Japan, South Korea, and Taiwan.

NoahAI News10/24/2025
Biogen Expands Immunology Pipeline with $1B Vanqua Bio Deal

Biogen Expands Immunology Pipeline with $1B Vanqua Bio Deal

Biogen, a leading pharmaceutical company, has announced a significant expansion of its immunology pipeline through a $1 billion deal with Vanqua Bio. The agreement centers on Vanqua's preclinical C5aR1 antagonist, a promising oral compound targeting neutrophil-mediated inflammation.

NoahAI News10/24/2025
Roche and Labcorp Lead Alzheimer's Diagnostic Revolution with FDA-Cleared Blood Test

Roche and Labcorp Lead Alzheimer's Diagnostic Revolution with FDA-Cleared Blood Test

In a significant advancement for Alzheimer's disease diagnostics, Roche has secured FDA clearance for its Elecsys pTau181 blood test, developed in collaboration with Eli Lilly. This minimally invasive test, designed for use in primary care settings, aims to assess early signs of Alzheimer's and other causes of cognitive decline in patients 55 years and older.

NoahAI News10/24/2025
Sanofi Halts RSV Vaccine Program for Toddlers Following Phase 3 Setback

Sanofi Halts RSV Vaccine Program for Toddlers Following Phase 3 Setback

Sanofi, the French pharmaceutical giant, has announced the termination of its respiratory syncytial virus (RSV) vaccine program for toddlers after disappointing results in a late-stage clinical trial. This development marks a significant shift in the company's RSV strategy and highlights the challenges in developing effective vaccines for young children.

NoahAI News10/24/2025
FDA Approves Return of GSK's Blenrep for Multiple Myeloma Treatment

FDA Approves Return of GSK's Blenrep for Multiple Myeloma Treatment

The Food and Drug Administration (FDA) has granted approval for the return of GSK's multiple myeloma drug Blenrep, marking a significant turnaround for a medication that was withdrawn from the U.S. market three years ago. The decision comes with specific conditions and represents a crucial development in the treatment landscape for multiple myeloma patients.

NoahAI News10/24/2025
Pharmaceutical Industry Faces Widespread Layoffs Amid Strategic Shifts

Pharmaceutical Industry Faces Widespread Layoffs Amid Strategic Shifts

In recent months, the pharmaceutical industry has seen a significant wave of layoffs and restructuring efforts as companies aim to streamline operations, cut costs, and refocus their strategic priorities. This trend has affected both major pharmaceutical giants and smaller biotech firms, with thousands of employees impacted across various locations.

NoahAI News10/24/2025
Viking Therapeutics Advances Metabolic Disease Pipeline Amid Industry Interest

Viking Therapeutics Advances Metabolic Disease Pipeline Amid Industry Interest

Viking Therapeutics, a small but promising player in the metabolic disease space, is making significant strides with its clinical programs for obesity and MASH (metabolic dysfunction-associated steatohepatitis). The company's progress comes at a time of heightened industry interest in these therapeutic areas, as evidenced by recent high-profile deals and acquisitions.

NoahAI News10/24/2025
Roche Intensifies Dealmaking Strategy, Eyes Further Acquisitions Amid Strong Financial Performance

Roche Intensifies Dealmaking Strategy, Eyes Further Acquisitions Amid Strong Financial Performance

Roche, the Swiss pharmaceutical giant, has signaled its intention to maintain an aggressive dealmaking pace following a series of high-profile acquisitions and partnerships. The company's CEO, Thomas Schinecker, emphasized during a recent third-quarter earnings call that Roche is "not done with BD [business development]," hinting at further strategic moves in the pipeline.

NoahAI News10/24/2025
Arcturus Therapeutics' mRNA Therapy for Cystic Fibrosis Shows Mixed Results in Phase II Trial

Arcturus Therapeutics' mRNA Therapy for Cystic Fibrosis Shows Mixed Results in Phase II Trial

Arcturus Therapeutics, a San Diego-based biotech company, has released interim data from its ongoing Phase II trial of ARCT-032, an inhaled mRNA therapy for cystic fibrosis (CF). The results, which have been met with mixed reactions from investors and analysts, reveal both challenges and potential promise for the experimental treatment.

NoahAI News10/24/2025
Molina Healthcare's Q3 Results Reveal Industry-Wide Cost Pressures

Molina Healthcare's Q3 Results Reveal Industry-Wide Cost Pressures

Molina Healthcare's third-quarter earnings report has sent shockwaves through the health insurance sector, highlighting significant cost pressures across the industry, particularly in the individual marketplace. The company's stock price plummeted 21% following the announcement of disappointing financial results, dragging down shares of other marketplace-heavy insurers in its wake.

NoahAI News10/24/2025
Alkermes' $2.1B Acquisition of Avadel Boosts Narcolepsy Drug Portfolio with Lumryz

Alkermes' $2.1B Acquisition of Avadel Boosts Narcolepsy Drug Portfolio with Lumryz

Alkermes to Acquire Avadel for $2.1B, Expanding Presence in Sleep Medicine MarketAlkermes plc has announced plans to acquire Avadel Pharmaceuticals in a deal worth up to $2.1 billion, marking a significant expansion into the sleep medicine market. The acquisition, expected to close in the first quarter of 2026, will give Alkermes immediate access to Avadel's narcolepsy drug Lumryz and lay the groundwork for the potential commercialization of its own narcolepsy candidate, alixorexton.

NoahAI News10/24/2025
Roche Faces Q3 Challenges Amid Currency Fluctuations, But Remains Optimistic for Future Growth

Roche Faces Q3 Challenges Amid Currency Fluctuations, But Remains Optimistic for Future Growth

Swiss pharmaceutical giant Roche reported a softer-than-expected third quarter performance, primarily due to exchange rate fluctuations and slower sales growth for key medicines. Despite these challenges, the company maintains a positive outlook for its long-term growth potential and resilience in the face of upcoming patent expirations.

NoahAI News10/24/2025
«1...242526...67»